Inovio Pharmaceuticals (INO) Common Equity (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Common Equity of $6.1 million for Q1 2026, down 74.82% sequentially from $24.1 million in Q4 2025, and down 88.16% YoY from $51.3 million in Q1 2025.
Inovio Pharmaceuticals (INO) Common Equity (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $6.1 million in Q1 2026.
- Quarterly Common Equity fell 88.16% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 88.16% YoY) and the FY2025 annual result came in at $24.1 million, down 64.82% from the prior year.
- Common Equity declined to $6.1 million in Q1 2026 per INO's latest filing, from $24.1 million in the prior quarter.
- Over five years, Common Equity peaked at $355.1 million in Q1 2022 and troughed at -$7.7 million in Q3 2025.
- A 5-year average of $129.5 million and a median of $96.7 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity sank 38.95% in 2022, then plunged 110.5% in 2025.
- Over 5 years, Common Equity stood at $222.4 million in 2022, then sank by 47.23% to $117.3 million in 2023, then plunged by 41.62% to $68.5 million in 2024, then sank by 64.82% to $24.1 million in 2025, then slumped by 74.82% to $6.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $6.1 million, $24.1 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 9.79 Bn |
| 10 | Inovio Pharmaceuticals | 95.49 Mn | 95.49 Mn | - | 4.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.37 Mn |
| Mar 31, 2026 | 6.07 Mn |
| Dec 31, 2025 | 24.10 Mn |
| Sep 30, 2025 | -7.72 Mn |
| Jun 30, 2025 | 28.53 Mn |
| Mar 31, 2025 | 51.25 Mn |
| Dec 31, 2024 | 68.50 Mn |
| Sep 30, 2024 | 73.54 Mn |
| Jun 30, 2024 | 96.74 Mn |
| Mar 31, 2024 | 94.44 Mn |
| Dec 31, 2023 | 117.35 Mn |
| Sep 30, 2023 | 138.16 Mn |
| Jun 30, 2023 | 169.37 Mn |
| Mar 31, 2023 | 199.21 Mn |
| Dec 31, 2022 | 222.36 Mn |
| Sep 30, 2022 | 266.70 Mn |
| Jun 30, 2022 | 297.67 Mn |
| Mar 31, 2022 | 355.09 Mn |
| Dec 31, 2021 | 399.67 Mn |
| Sep 30, 2021 | 453.57 Mn |